Search by Journal
- HOME
- > Search by Journal
- > Neurological Therapeutics
Neurological Therapeutics
Volume 40, Issue 4 / 2023
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
What is the multiple sclerosis? 藤原一男* Neurological Therapeutics 40(4): 419-419, 2023. |
|---|
|
|
Special symposium 3: PMDA Joint Symposium PMDA Joint Symposium Words from the host 佐久嶋研, 中村治雅 Neurological Therapeutics 40(4): 420-420, 2023. |
|---|
|
|
Perspectives for development of new medical technologies and role of PMDA Haruko YAMAMOTO Neurological Therapeutics 40(4): 421-424, 2023. |
|---|
|
|
An activity of ASENT and my Parkinson's disease study Maral Mouradian* Neurological Therapeutics 40(4): 425-425, 2023. |
|---|
|
|
Development of the drug that regulates neuronal network, immune system and blood-brain barrier Toshihide YAMASHITA Neurological Therapeutics 40(4): 426-431, 2023. |
|---|
|
|
Diagnosis and treatment of facial pain Teiji YAMAMOTO Neurological Therapeutics 40(4): 432-437, 2023. |
|---|
|
|
Recent advances in CNS inflammatory demyelinating diseases Ichiro NAKASHIMA Neurological Therapeutics 40(4): 438-440, 2023. |
|---|
|
|
Term of the how to make data host making the how to make data future making the future symposium 10 橋詰淳, 三澤園子 Neurological Therapeutics 40(4): 441-441, 2023. |
|---|
|
|
How to create data that builds the future, toward the use of real world data / real world evidence. Introduction Harumasa NAKAMURA Neurological Therapeutics 40(4): 442-444, 2023. |
|---|
|
|
Trend of the inflection of RWD judging from 2 pharmaceutical affair administration 安藤友紀* Neurological Therapeutics 40(4): 445-445, 2023. |
|---|
|
|
Trends in real world data utilization in rare diseases Yoshihisa YAMANO Neurological Therapeutics 40(4): 446-448, 2023. |
|---|
|
|
Trend of the inflection of RWD using 4 electronic medical charts 小澤郷司* Neurological Therapeutics 40(4): 449-449, 2023. |
|---|
|
|
Development and utilization of RWD in foreign countries and Japan - from the perspective of pharmaceutical companies - Nobutomo MATSUI Neurological Therapeutics 40(4): 450-453, 2023. |
|---|
|
|
Term of the Parkinson disease practice host to make the Parkinson disease practice advanced age which symposium 11 makes the advanced age 波田野琢 Neurological Therapeutics 40(4): 454-454, 2023. |
|---|
|
|
Epidemiology of Parkinson disease in the elderly and future issues Shin-ichi UENO, Taku HATANO, Nobutaka HATTORI Neurological Therapeutics 40(4): 455-457, 2023. |
|---|
|
|
Clinical practice for the elderly living with Parkinson disease : lack of direct evidence - A narrative viewpoint Yuji SAITOH Neurological Therapeutics 40(4): 458-462, 2023. |
|---|
|
|
Understanding the pathophysiology of Parkinson disease in the elderly. Characteristics of Parkinson disease observed through pathological examination Renpei SENGOKU Neurological Therapeutics 40(4): 463-466, 2023. |
|---|
|
|
We approach in the condition of a patient of the neurodegenerative parkinsonism of elderly people in the imaging technology in the living body using 4 advanced PET probe 遠藤浩信*, 小野麻衣子*, 松岡究*, 互健二*, 河村和紀*, 張明栄*, 樋口真人* Neurological Therapeutics 40(4): 467-467, 2023. |
|---|
|
|
Managements of Parkinson disease in the elderly from the standpoint of university hospital Kazuhiro IWAOKA, Tetsuya MAEDA Neurological Therapeutics 40(4): 468-471, 2023. |
|---|
|
|
From the situation of management - community medical care of 6 advanced age Parkinson's disease - 和手麗香* Neurological Therapeutics 40(4): 472-472, 2023. |
|---|
|
|
Term of the condition of a patient front line host of the condition of a patient front line autoimmunity-related neuropathy of the neuropathy autoimmunity-related symposium 12: 海田賢一 Neurological Therapeutics 40(4): 473-473, 2023. |
|---|
|
|
COVID-19 and Guillain-Barre syndrome Motoi KUWAHARA Neurological Therapeutics 40(4): 474-477, 2023. |
|---|
|
|
Trend of the new treatment of 2 Guillain-Barre syndrome 三澤園子* Neurological Therapeutics 40(4): 478-478, 2023. |
|---|
|
|
Anti-neurofascin 155 antibody-positive and anti-contactin-1 antibody-positive nodopathies Hidenori OGATA Neurological Therapeutics 40(4): 479-483, 2023. |
|---|
|
|
Expected future therapies for CIDP : Update Michiaki KOGA Neurological Therapeutics 40(4): 484-487, 2023. |
|---|
|
|
It is Restless legs syndrome symposium 13: It is Restless legs syndrome for standard neurotherapeutics to be based on Grade system: It is the term of the host for standard neurotherapeutics to be based on Grade system 坪井義夫 Neurological Therapeutics 40(4): 488-488, 2023. |
|---|
|
|
Disease concept of restless legs syndrome Tomoyuki MIYAMOTO Neurological Therapeutics 40(4): 489-493, 2023. |
|---|
|
|
Etiology and pathophysiology of restless legs syndrome Masayuki MIYAMOTO Neurological Therapeutics 40(4): 494-497, 2023. |
|---|
|
|
3. Treatment of restless legs syndrome 岡靖哲* Neurological Therapeutics 40(4): 498-498, 2023. |
|---|
|
|
Restless legs syndrome (RLS) clinical practice guideline with regard to Minds Handbook for clinical practice guideline development 2020 Noriko KOJIMAHARA Neurological Therapeutics 40(4): 499-502, 2023. |
|---|
|
|
Symposium 14: Frontline of preemptive dementia care: Current status and challenges Frontline of preemptive dementia care: Current status and challenges Words from the host 冨本秀和*, 秋山治彦** Neurological Therapeutics 40(4): 503-503, 2023. |
|---|
|
|
Current status and prospects of disease-modifying therapies for Alzheimer disease Kenjiro ONO Neurological Therapeutics 40(4): 504-507, 2023. |
|---|
|
|
Biomarkers for Alzheimer disease in preemptive medicine Kenji WADA Neurological Therapeutics 40(4): 508-510, 2023. |
|---|
|
|
Clearing amyloid β from the brain Masafumi IHARA Neurological Therapeutics 40(4): 511-515, 2023. |
|---|
|
|
Journey towards achieving preemptive medicine for dementia through imaging Hitoshi SHIMADA Neurological Therapeutics 40(4): 516-520, 2023. |
|---|
|
|
Platform research for the development of disease-modifying therapies for Alzheimer disease : J-ADNI and J-TRC Takeshi IWATSUBO Neurological Therapeutics 40(4): 521-525, 2023. |
|---|
|
|
Oligonucleotide N-of-1 strategies for treating rare neurological diseases Tojo NAKAYAMA*,**, Takanori YOKOTA* Neurological Therapeutics 40(4): 526-530, 2023. |
|---|
|
|
The current state of initiative on rare and undiagnosed disease (IRUD) in Japan Hidehiro MIZUSAWA Neurological Therapeutics 40(4): 531-536, 2023. |
|---|
|
|
Way of thinking of the non-clinical safety assessment in the N-of-1 drug discovery of 4 nucleic acid pharmaceutical products 真木一茂* Neurological Therapeutics 40(4): 537-537, 2023. |
|---|
|
|
Challenges towards N-of-one medicine from a view point of industry Yasushi KAJII Neurological Therapeutics 40(4): 538-540, 2023. |
|---|
|
|
It is the term of the paradigm shift host of the paradigm shift migraine headache treatment of the migraine headache treatment symposium 16 平田幸一 Neurological Therapeutics 40(4): 541-541, 2023. |
|---|
|
|
Clinical Practice Guideline for Headache Disorders 2021 : A new compass for navigating headache management Mamoru SHIBATA Neurological Therapeutics 40(4): 542-546, 2023. |
|---|
|
|
Impediment of migraine Muneto TATSUMOTO Neurological Therapeutics 40(4): 547-549, 2023. |
|---|
|
|
Migraine therapy from the pathogenesis of calcitonin gene-related peptide (CGRP) Kazumasa SAIGOH Neurological Therapeutics 40(4): 550-554, 2023. |
|---|
|
|
5-HT1F receptor agonist (ditan) Eiichiro NAGATA Neurological Therapeutics 40(4): 555-559, 2023. |
|---|
|
|
Term of the latest trend host of a diagnosis, the treatment of the nerve infection that wants to know the latest trend of a diagnosis, the treatment of the nerve infection that we want to know by all means by all means symposium 17 山野嘉久 Neurological Therapeutics 40(4): 560-560, 2023. |
|---|
|
|
Use of the FilmArray(R) system for the diagnosis of meningitis and encephalitis Hideto NAKAJIMA Neurological Therapeutics 40(4): 561-563, 2023. |
|---|
|
|
Drug-associated progressive multifocal leukoencephalopathy Masaaki NIINO Neurological Therapeutics 40(4): 564-566, 2023. |
|---|
|
|
The current situation and measures of 3 HIV-related cognitive impairment 岡慎一* Neurological Therapeutics 40(4): 567-567, 2023. |
|---|
|
|
4 COVID 19 aftereffects: Clinical practice and the condition of a patient of neuro-PASC 下畑享良* Neurological Therapeutics 40(4): 568-568, 2023. |
|---|
|
|
It is the term of the front line host of the treatment of the front line amyotrophic lateral sclerosis (ALS) of the treatment of the amyotrophic lateral sclerosis (ALS) symposium 18 熱田直樹, 青木正志 Neurological Therapeutics 40(4): 569-569, 2023. |
|---|
|
|
The interactivity of therapeutic drug development - condition of a patient elucidation in 1 ALS and future development 漆谷真* Neurological Therapeutics 40(4): 570-570, 2023. |
|---|
|
|
Approach to patients and caregivers based on the latest knowledge Osamu KANO, Takehisa HIRAYAMA, Masaru YANAGIHASHI Neurological Therapeutics 40(4): 571-574, 2023. |
|---|
|
|
An approach to non-motor symptoms of patients with amyotrophic lateral sclerosis : an update on clinical management Hitoshi WARITA Neurological Therapeutics 40(4): 575-579, 2023. |
|---|
|
|
Swallowing disturbance and nutritional dysfunction in amyotrophic lateral sclerosis Toshio SHIMIZU Neurological Therapeutics 40(4): 580-584, 2023. |
|---|
|
|
Respiratory management of amyotrophic lateral sclerosis : Approaches to respiratory dysfunction based on current knowledge Takuji FUJITA, Kenichiro NAKAZAWA Neurological Therapeutics 40(4): 585-587, 2023. |
|---|
|
|
Rehabilitation in amyotrophic lateral sclerosis Mitsuya MORITA Neurological Therapeutics 40(4): 588-591, 2023. |
|---|
|
|
It is the term of clinical practice and the condition of a patient host of clinical practice and condition of a patient MOG antibody associated diseases (MOGAD) of MOG antibody associated diseases (MOGAD) symposium 19 高井良樹, 森雅裕 Neurological Therapeutics 40(4): 592-592, 2023. |
|---|
|
|
Epidemiology and clinical picture of 1 MOG antibody associated diseases 中村正史*1, 小川諒*1, 藤盛寿一*1, 鵜沢顕之*2, 佐藤泰憲*3, 長島健悟*4, 栗山長門*5,*6, 中島一郎*1 Neurological Therapeutics 40(4): 593-593, 2023. |
|---|
|
|
Radiological features of MOGAD Masahiro MORI Neurological Therapeutics 40(4): 594-597, 2023. |
|---|
|
|
Pathology and pathogenesis of Myelin oligodendrocyte glycoprotein antibody-related diseases Yoshiki TAKAI*, Tatsuro MISU*, Kazuo FUJIHARA**, Masashi AOKI* Neurological Therapeutics 40(4): 598-605, 2023. |
|---|
|
|
Pathophysiology and treatment of myelin-oligodendrocyte glycoprotein antibody-associated diseases Norio CHIHARA Neurological Therapeutics 40(4): 606-609, 2023. |
|---|
|
|
It is the term of the condition of a patient and the treatment Update host of the condition of a patient and treatment Update epilepsy of epilepsy symposium 20 池田昭夫 Neurological Therapeutics 40(4): 610-610, 2023. |
|---|
|
|
Novel, multidisciplinary findings to solve pathogenesis of epilepsy : role of astrocytes in impairment of extracellular potassium homeostasis Akio IKEDA Neurological Therapeutics 40(4): 611-616, 2023. |
|---|
|
|
Advancement of neurophyiosologic and radiologic examinations for epilepsy surgery Riki MATSUMOTO Neurological Therapeutics 40(4): 617-621, 2023. |
|---|
|
|
Epilepsy treatment device ; Vagus nerve stimulation (VNS) for medically intractable epilepy Naoki AKAMATSU Neurological Therapeutics 40(4): 622-624, 2023. |
|---|
|
|
Progress ... of medical treatment - these days of 4 epilepsy 神一敬* Neurological Therapeutics 40(4): 625-625, 2023. |
|---|
|
|
Symposium 21: Neuroradiological findings in degenerative diseases Neuroradiological findings in degenerative diseases Words from the host 徳丸阿耶 Neurological Therapeutics 40(4): 626-626, 2023. |
|---|
|
|
Imaging diagnosis of neurodegenerative diseases : Significance of clinical-imaging-pathological relationship Aya M.TOKUMARU Neurological Therapeutics 40(4): 627-632, 2023. |
|---|
|
|
Voxel-based morphometry (VBM) analysis of brain MRI in patients with neurodegenerative disease Shingo KAKEDA*, Keita WATANABE** Neurological Therapeutics 40(4): 633-636, 2023. |
|---|
|
|
Noninvasive magnetic resonance imaging measures of glymphatic system activity Koji KAMAGATA, Kaito TAKABAYASHI Neurological Therapeutics 40(4): 637-641, 2023. |
|---|
|
|
Clinical application of quantitative susceptibility mapping (QSM) in 4 neurodegenerative diseases 工藤與亮* Neurological Therapeutics 40(4): 642-642, 2023. |
|---|
|
|
It is the term of the achievement host of the cranial nerve physician in the achievement nerve first aid of the cranial nerve physician in the nerve first aid symposium 22 西山和利 Neurological Therapeutics 40(4): 643-643, 2023. |
|---|
|
|
1. Detection and treatment of non-convulsive status epilepticus in acute stroke treatment 永井俊行* Neurological Therapeutics 40(4): 644-644, 2023. |
|---|
|
|
Recanalization therapy for acute stroke and the role of neurologists Yuki KAMIYA Neurological Therapeutics 40(4): 645-649, 2023. |
|---|
|
|
Emergency control of 3 myasthenia gravis 鈴木重明* Neurological Therapeutics 40(4): 650-650, 2023. |
|---|
|
|
Emergency medicine for the patients of intractable neurological diseases Shimon ISHIDA Neurological Therapeutics 40(4): 651-653, 2023. |
|---|
|
|
It is the term of the team approach in medical care host of the team approach in medical care neurotherapeutics of the neurotherapeutics medical staff symposium 1 竹川英宏, 作石かおり Neurological Therapeutics 40(4): 654-654, 2023. |
|---|
|
|
Team medical care for people with multiple sclerosis - Our role to know "the disease" and "the person's live" - Toshiyuki FUKAZAWA, Kazuko NISHIYAMA Neurological Therapeutics 40(4): 655-658, 2023. |
|---|
|
|
The multi-type of job cooperation in 2 epilepsy practice 神一敬* Neurological Therapeutics 40(4): 659-659, 2023. |
|---|
|
|
Collaboration among medical staff in stroke team care Yusuke YAKUSHIJI, Takenobu KUNIEDA Neurological Therapeutics 40(4): 660-663, 2023. |
|---|
|
|
Role of a viewpoint and the patients' association of patients with 4 multiple sclerosis 中田郷子* Neurological Therapeutics 40(4): 664-664, 2023. |
|---|
|
|
Team approach in medical care in 5 ALS practice 荻野美恵子* Neurological Therapeutics 40(4): 665-665, 2023. |
|---|
|
|
A case of upper extremity neuralgic amyotrophy following posterior lumbar interbody fusion Yasushi HOSOI, Miharu YANAGIDA, Tatsuhiro KAWANO, Yusuke OTAKE, Michiko ITO Neurological Therapeutics 40(4): 666-669, 2023. |
|---|
